{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:05:10Z","timestamp":1793714710561,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T00:00:00Z","timestamp":1558396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Sailing Program","award":["16YF1401100"],"award-info":[{"award-number":["16YF1401100"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81802596"],"award-info":[{"award-number":["No.81802596"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["17ZR1403500"],"award-info":[{"award-number":["17ZR1403500"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13048-019-0524-2","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T18:15:54Z","timestamp":1558462554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Development and validation of SIRT3-related nomogram predictive of overall survival in patients with serous ovarian cancer"],"prefix":"10.1186","volume":"12","author":[{"given":"Jun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiran","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-5609","authenticated-orcid":false,"given":"Xiaohong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,21]]},"reference":[{"key":"524_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/nrclinonc.2013.5","volume":"10","author":"RL Coleman","year":"2013","unstructured":"Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10:211\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"524_CR2","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/gb-2004-5-5-224","volume":"5","author":"BJ North","year":"2004","unstructured":"North BJ, Verdin E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 2004;5:224.","journal-title":"Genome Biol"},{"key":"524_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/1479-7364-5-5-485","volume":"5","author":"A Vassilopoulos","year":"2011","unstructured":"Vassilopoulos A, Fritz KS, Petersen DR, Gius D. The human sirtuin family: evolutionary divergences and functions. Hum Genomics. 2011;5:485\u201396.","journal-title":"Hum Genomics"},{"key":"524_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.yexcr.2018.03.030","volume":"367","author":"Y Wu","year":"2018","unstructured":"Wu Y, Gao WN, Xue YN, Zhang LC, Zhang JJ, Lu SY, Yan XY, Yu HM, Su J, Sun LK. SIRT3 aggravates metformin-induced energy stress and apoptosis in ovarian cancer cells. Exp Cell Res. 2018;367:137\u201349.","journal-title":"Exp Cell Res"},{"key":"524_CR5","first-page":"4431","volume":"22","author":"W Jiang","year":"2018","unstructured":"Jiang W, Jiang P, Yang R, Liu DF. Functional role of SIRT1-induced HMGB1 expression and acetylation in migration, invasion and angiogenesis of ovarian cancer. Eur Rev Med Pharmacol Sci. 2018;22:4431\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"524_CR6","doi-asserted-by":"publisher","first-page":"538","DOI":"10.3389\/fonc.2018.00538","volume":"8","author":"JS Bae","year":"2018","unstructured":"Bae JS, Noh SJ, Kim KM, Park SH, Hussein UK, Park HS, Park BH, Ha SH, Lee H, Chung MJ, Moon WS, Cho DH, Jang KY. SIRT6 is involved in the progression of ovarian carcinomas via beta-catenin-mediated epithelial to mesenchymal transition. Front Oncol. 2018;8:538.","journal-title":"Front Oncol"},{"key":"524_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1159\/000458744","volume":"41","author":"U Ray","year":"2017","unstructured":"Ray U, Roy SS, Chowdhury SR. Lysophosphatidic acid promotes epithelial to mesenchymal transition in ovarian Cancer cells by repressing SIRT1. Cell Physiol Biochem. 2017;41:795\u2013805.","journal-title":"Cell Physiol Biochem"},{"key":"524_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.tranon.2017.05.005","volume":"10","author":"DH Mvunta","year":"2017","unstructured":"Mvunta DH, Miyamoto T, Asaka R, Yamada Y, Ando H, Higuchi S, Ida K, Kashima H, Shiozawa T. SIRT1 regulates the Chemoresistance and invasiveness of ovarian carcinoma cells. Transl Oncol. 2017;10:621\u201331.","journal-title":"Transl Oncol"},{"key":"524_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.bbrc.2016.05.098","volume":"475","author":"XC Dong","year":"2016","unstructured":"Dong XC, Jing LM, Wang WX, Gao YX. Down-regulation of SIRT3 promotes ovarian carcinoma metastasis. Biochem Biophys Res Commun. 2016;475:245\u201350.","journal-title":"Biochem Biophys Res Commun"},{"key":"524_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s12032-015-0706-8","volume":"32","author":"T Shuang","year":"2015","unstructured":"Shuang T, Wang M, Zhou Y, Shi C. Over-expression of Sirt1 contributes to chemoresistance and indicates poor prognosis in serous epithelial ovarian cancer (EOC). Med Oncol. 2015;32:260.","journal-title":"Med Oncol"},{"key":"524_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41389-018-0027-9","volume":"7","author":"G Pinton","year":"2018","unstructured":"Pinton G, Nilsson S, Moro L. Targeting estrogen receptor beta (ERbeta) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ERbeta expression and functionality. Oncogenesis. 2018;7:15.","journal-title":"Oncogenesis"},{"key":"524_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/acel.12538","volume":"16","author":"A Ansari","year":"2017","unstructured":"Ansari A, Rahman MS, Saha SK, Saikot FK, Deep A, Kim KH. Function of the SIRT3 mitochondrial deacetylase in cellular physiology, cancer, and neurodegenerative disease. Aging Cell. 2017;16:4\u201316.","journal-title":"Aging Cell"},{"key":"524_CR13","doi-asserted-by":"crossref","unstructured":"Torrens-Mas M, Oliver J, Roca P, Sastre-Serra J. SIRT3: oncogene and tumor suppressor in Cancer. Cancers (Basel). 2017;9.","DOI":"10.3390\/cancers9070090"},{"key":"524_CR14","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1158\/0008-5472.CAN-15-2733","volume":"76","author":"J George","year":"2016","unstructured":"George J, Ahmad N. Mitochondrial Sirtuins in Cancer: emerging roles and therapeutic potential. Cancer Res. 2016;76:2500\u20136.","journal-title":"Cancer Res"},{"key":"524_CR15","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s13277-013-0726-y","volume":"34","author":"CC Lai","year":"2013","unstructured":"Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu ML, Hsu CM, Yang MY. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol. 2013;34:1847\u201354.","journal-title":"Tumour Biol"},{"key":"524_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.bbrc.2013.11.068","volume":"443","author":"B Yang","year":"2014","unstructured":"Yang B, Fu X, Shao L, Ding Y, Zeng D. Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer. Biochem Biophys Res Commun. 2014;443:156\u201360.","journal-title":"Biochem Biophys Res Commun"},{"key":"524_CR17","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1074\/jbc.M115.702076","volume":"291","author":"W Yu","year":"2016","unstructured":"Yu W, Denu RA, Krautkramer KA, Grindle KM, Yang DT, Asimakopoulos F, Hematti P, Denu JM. Loss of SIRT3 provides growth advantage for B cell malignancies. J Biol Chem. 2016;291:3268\u201379.","journal-title":"J Biol Chem"},{"key":"524_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-014-0103-8","volume":"31","author":"SM Yan","year":"2014","unstructured":"Yan SM, Han X, Han PJ, Chen HM, Huang LY, Li Y. SIRT3 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Med Oncol. 2014;31:103.","journal-title":"Med Oncol"},{"key":"524_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/cncr.25676","volume":"117","author":"TY Alhazzazi","year":"2011","unstructured":"Alhazzazi TY, Kamarajan P, Joo N, Huang JY, Verdin E, D'Silva NJ, Kapila YL. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer. 2011;117:1670\u20138.","journal-title":"Cancer"},{"key":"524_CR20","first-page":"3047","volume":"33","author":"R Shackelford","year":"2013","unstructured":"Shackelford R, Hirsh S, Henry K, Abdel-Mageed A, Kandil E, Coppola D. Nicotinamide phosphoribosyltransferase and SIRT3 expression are increased in well-differentiated thyroid carcinomas. Anticancer Res. 2013;33:3047\u201352.","journal-title":"Anticancer Res"},{"key":"524_CR21","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/sj.bjc.6603384","volume":"95","author":"N Ashraf","year":"2006","unstructured":"Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, Shiels PG. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer. 2006;95:1056\u201361.","journal-title":"Br J Cancer"},{"key":"524_CR22","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.humpath.2014.01.004","volume":"45","author":"MM Desouki","year":"2014","unstructured":"Desouki MM, Doubinskaia I, Gius D, Abdulkadir SA. Decreased mitochondrial SIRT3 expression is a potential molecular biomarker associated with poor outcome in breast cancer. Hum Pathol. 2014;45:1071\u20137.","journal-title":"Hum Pathol"},{"key":"524_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.gene.2016.04.023","volume":"586","author":"M Igci","year":"2016","unstructured":"Igci M, Kalender ME, Borazan E, Bozgeyik I, Bayraktar R, Bozgeyik E, Camci C, Arslan A. High-throughput screening of Sirtuin family of genes in breast cancer. Gene. 2016;586:123\u20138.","journal-title":"Gene"},{"key":"524_CR24","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1002\/cam4.1691","volume":"7","author":"Y Yang","year":"2018","unstructured":"Yang Y, Cao Y, Chen L, Liu F, Qi Z, Cheng X, Wang Z. Cryptotanshinone suppresses cell proliferation and glucose metabolism via STAT3\/SIRT3 signaling pathway in ovarian cancer cells. Cancer Med. 2018;7:4610\u20138.","journal-title":"Cancer Med"},{"key":"524_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159801","volume":"11","author":"FY Yu","year":"2016","unstructured":"Yu FY, Xu Q, Wu DD, Lau AT, Xu YM. The prognostic and Clinicopathological roles of Sirtuin-3 in various cancers. PLoS One. 2016;11:e0159801.","journal-title":"PLoS One"},{"key":"524_CR26","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.prp.2017.07.023","volume":"213","author":"S Huang","year":"2017","unstructured":"Huang S, Chen X, Zheng J, Huang Y, Song L, Yin Y, Xiong J. Low SIRT3 expression contributes to tumor progression, development and poor prognosis in human pancreatic carcinoma. Pathol Res Pract. 2017;213:1419\u201323.","journal-title":"Pathol Res Pract"},{"key":"524_CR27","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1002\/jcp.26443","volume":"233","author":"M Torrens-Mas","year":"2018","unstructured":"Torrens-Mas M, Hernandez-Lopez R, Oliver J, Roca P, Sastre-Serra J. Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer. J Cell Physiol. 2018;233:6067\u201376.","journal-title":"J Cell Physiol"},{"key":"524_CR28","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.2147\/OTT.S157724","volume":"11","author":"G Huang","year":"2018","unstructured":"Huang G, Zhu G. Sirtuin-4 (SIRT4), a therapeutic target with oncogenic and tumor-suppressive activity in cancer. Onco Targets Ther. 2018;11:3395\u2013400.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"524_CR29","doi-asserted-by":"publisher","first-page":"e45124","DOI":"10.15252\/embr.201745124","volume":"19","author":"Xiu\u2010Fei Chen","year":"2018","unstructured":"Chen XF, Tian MX, Sun RQ, Zhang ML, Zhou LS, Jin L, Chen LL, Zhou WJ, Duan KL, Chen YJ, Gao C, Cheng ZL, Wang F, Zhang JY, Sun YP, Yu HX, Zhao YZ, Yang Y, Liu WR, Shi YH, Xiong Y, Guan KL, Ye D. SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Rep. 2018;19.","journal-title":"EMBO reports"},{"key":"524_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1878-0261.12408","volume":"13","author":"L Shi","year":"2019","unstructured":"Shi L, Yan H, An S, Shen M, Jia W, Zhang R, Zhao L, Huang G, Liu J. SIRT5-mediated deacetylation of LDHB promotes autophagy and tumorigenesis in colorectal cancer. Mol Oncol. 2019;13:358\u201375.","journal-title":"Mol Oncol"},{"key":"524_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/IGC.0000000000000350","volume":"36","author":"G Zhang","year":"2015","unstructured":"Zhang G, Liu Z, Qin S, Li K. Decreased expression of SIRT6 promotes tumor cell growth correlates closely with poor prognosis of ovarian cancer. Eur J Gynaecol Oncol. 2015;36:629\u201332.","journal-title":"Eur J Gynaecol Oncol"},{"key":"524_CR32","first-page":"818","volume":"19","author":"J Zhang","year":"2015","unstructured":"Zhang J, Yin XJ, Xu CJ, Ning YX, Chen M, Zhang H, Chen SF, Yao LQ. The histone deacetylase SIRT6 inhibits ovarian cancer cell proliferation via down-regulation of notch 3 expression. Eur Rev Med Pharmacol Sci. 2015;19:818\u201324.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"524_CR33","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.7314\/APJCP.2015.16.8.3573","volume":"16","author":"HL Wang","year":"2015","unstructured":"Wang HL, Lu RQ, Xie SH, Zheng H, Wen XM, Gao X, Guo L. SIRT7 exhibits oncogenic potential in human ovarian Cancer cells. Asian Pac J Cancer Prev. 2015;16:3573\u20137.","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0524-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13048-019-0524-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-019-0524-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T23:20:17Z","timestamp":1589930417000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-019-0524-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,21]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["524"],"URL":"https:\/\/doi.org\/10.1186\/s13048-019-0524-2","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,21]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All data in present study are obtained from TCGA and GEO databases, which have received ethics approval and consent to participate. The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All data in present study are obtained from TCGA and GEO databases, which have received consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"47"}}